Tech trio aims to help breast cancer survivors remember daily pills
NCT ID NCT06865755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a system combining a smartphone app, a special pill bottle that records when it's opened, and a Fitbit can help breast cancer survivors take their long-term hormone therapy more consistently. Fifteen survivors aged 21-70 will use the system for six months and share their experiences through surveys. The goal is to see if this technology makes it easier to stick to the daily medication routine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 70 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * are English-speaking and reading; * are between ages 21 and 70 years; * are diagnosed with stage 0-3 breast cancer in the past 5 years; * have completed all surgery, radiation, and chemotherapy, except endocrine therapy; * are prescribed endocrine therapy; * do not have a physical impairment that would prevent them from using the MM system; * are able to provide informed consent; * are willing and able to use the MM system for 6 months; * have an Iphone or Android phone.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer early stage breast cancer (stage 1-3) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
San Diego State University
San Diego, California, 92120, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can treating less breast tissue mean fewer radiation side effects?
- Gene test may Fine-Tune breast cancer therapy for younger women
- Can adding pyrotinib shrink HER2-Positive breast tumors before surgery?
- Exercise as medicine: can a 12-Week program shift breast cancer biomarkers?
- Exercise during chemo: a new weapon to preserve strength?